Xinpeng Cheng

Title: Xinpeng Cheng: Innovator in Targeted Degradation of Bruton's Tyrosine Kinase

Introduction

Xinpeng Cheng is a notable inventor based in Watertown, MA (US). He has made significant contributions to the field of biochemistry, particularly in the development of compounds that target Bruton's tyrosine kinase (BTK). His work is crucial for advancing treatments for disorders related to Btk activity.

Latest Patents

Xinpeng Cheng holds a patent for "Compounds for targeting degradation of Bruton's tyrosine kinase." This patent describes compounds of Formula (A): BTK-L-DSM (A) or a pharmaceutically acceptable salt thereof. The compounds are designed to activate the selective ubiquitination of Btk proteins via the ubiquitin-proteasome pathways, leading to the degradation of Btk proteins. This innovation has potential applications in treating disorders responsive to modulation of Btk activity.

Career Highlights

Xinpeng Cheng is currently associated with Biogen MA Inc., where he continues to work on groundbreaking research in the field of biotechnology. His expertise in developing targeted therapies has positioned him as a key figure in the industry.

Collaborations

Xinpeng collaborates with Eric Stefan, contributing to the advancement of their research initiatives. Their combined efforts aim to enhance the understanding and treatment of diseases related to Btk.

Conclusion

Xinpeng Cheng's innovative work in the field of targeted degradation of Bruton's tyrosine kinase represents a significant advancement in biochemistry. His contributions are paving the way for new therapeutic strategies in treating related disorders.